Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine – A randomized clinical trial
Authors:
- 1 November 2018
- Vol. 36 (46) , 7017-7024
Abstract
No abstract availableKeywords
Funding Information
- Quebec Ministry of Health and Social Services
- Bill and Melinda Gates Foundation
This publication has 33 references indexed in Scilit:
- Association of Varying Number of Doses of Quadrivalent Human Papillomavirus Vaccine With Incidence of CondylomaJAMA, 2014
- Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage studyBMC Medicine, 2013
- Strongly Decreased Risk of Genital Warts After Vaccination Against Human Papillomavirus: Nationwide Follow-up of Vaccinated and Unvaccinated Girls in DenmarkClinical Infectious Diseases, 2013
- Potential impact of a nine-valent vaccine in human papillomavirus related cervical diseaseInfectious Agents and Cancer, 2012
- Human Papillomavirus Vaccines – Immune ResponsesVaccine, 2012
- Humoral, Mucosal, and Cell-Mediated Immunity Against Vaccine and Nonvaccine Genotypes After Administration of Quadrivalent Human Papillomavirus Vaccine to HIV-Infected ChildrenThe Journal of Infectious Diseases, 2012
- Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 yearsHuman Vaccines, 2011
- Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 VaccineJNCI: Journal of the National Cancer Institute, 2011
- Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trialBMJ, 2010
- Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted, Adsorbed) [Cervarix???]???BioDrugs, 2008